SciClone (NASDAQ:SCLN), a U.S.-based pharmaceutical company that sells licensed drugs on the Chinese market, was down 21% for November after poor quarterly results. In this video, Motley Fool health care analyst David Williamson discusses how a  price reduction imposed by the Chinese government on its lead drug, Zadaxin, affected sales. Though the company was able to mitigate the damage, the company's integration of its acquisition of NovaMed isn't going as hoped, which is another factor hurting the company at the moment. Given its strong cash flow, is the sell-off a buying opportunity, or is there additional uncertainty on the horizon?

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.